FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

US health advisers are currently debating a new type of flu vaccine developed by Moderna, known as mFlusvia, which utilizes the same mRNA technology instrumental during the Covid-19 pandemic. Moderna is seeking FDA approval for this shot specifically for individuals aged 50 and older. This FDA advisory committee meeting is a crucial step in the approval process before the upcoming winter flu season. If approved, mFlusvia would represent a significant advancement as the first mRNA-based flu vaccine, offering a new option for a vulnerable demographic.